Literature DB >> 20299338

Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD.

Csaba P Kovesdy1, Vitalie Ureche, Jun L Lu, Kamyar Kalantar-Zadeh.   

Abstract

BACKGROUND: Serum alkaline phosphatase (ALP) increases in patients with chronic kidney disease (CKD) and high-turnover bone disease. ALP may represent an adjunct marker of high bone turnover devoid of drawbacks of serum parathyroid hormone (PTH), and it may also be associated with cardiovascular calcification in CKD. Higher ALP has been recently associated with increased mortality and coronary calcification in dialysis patients. In pre-dialysis CKD patients, this association is not clear.
METHODS: We examined the association of baseline, time-varying and time-averaged ALP with all-cause mortality and the composite of pre-dialysis mortality or end-stage renal disease in a historical prospective cohort of 1158 male veterans with pre-dialysis CKD from a single institution by using multivariable-adjusted Cox models.
RESULTS: Higher ALP was associated with increased mortality irrespective of the statistical model. Time-averaged ALP displayed a consistent linear association with mortality: a 50-U/L higher serum ALP was associated with a multivariable-adjusted death hazard ratio (95% confidence interval) of 1.17 (1.08-1.28), P < 0.001. Baseline and time-varying ALP showed non-linear associations with mortality, with serum levels above 70 U/L in all models and with lower levels in time-varying models. Associations between ALP levels and the composite outcomes were similar. However, compared to serum PTH, mortality predictability of ALP appeared more incremental.
CONCLUSIONS: Elevated ALP is associated with increased mortality in patients with pre-dialysis CKD. Low ALP appears to be associated with short-term mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20299338      PMCID: PMC2948834          DOI: 10.1093/ndt/gfq144

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  34 in total

Review 1.  Cohort studies: marching forward.

Authors:  Ravi Thadhani; Marcello Tonelli
Journal:  Clin J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 8.237

2.  Bone markers predict cardiovascular events in chronic kidney disease.

Authors:  Astrid Fahrleitner-Pammer; Johann Herberth; Steven R Browning; Barbara Obermayer-Pietsch; Gerhard Wirnsberger; Herwig Holzer; Harald Dobnig; Hartmut H Malluche
Journal:  J Bone Miner Res       Date:  2008-11       Impact factor: 6.741

3.  Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.

Authors:  Deborah L Regidor; Csaba P Kovesdy; Rajnish Mehrotra; Mehdi Rambod; Jennie Jing; Charles J McAllister; David Van Wyck; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 10.121

4.  Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification.

Authors:  K A Lomashvili; P Garg; S Narisawa; J L Millan; W C O'Neill
Journal:  Kidney Int       Date:  2008-02-20       Impact factor: 10.612

Review 5.  Bone and mineral disorders in pre-dialysis CKD.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

6.  Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease.

Authors:  C P Kovesdy; S Ahmadzadeh; J E Anderson; K Kalantar-Zadeh
Journal:  Kidney Int       Date:  2008-03-12       Impact factor: 10.612

7.  Role for alkaline phosphatase as an inducer of vascular calcification in renal failure?

Authors:  M Schoppet; C M Shanahan
Journal:  Kidney Int       Date:  2008-05       Impact factor: 10.612

8.  High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients.

Authors:  Nora Voormolen; Marlies Noordzij; Diana C Grootendorst; Ivo Beetz; Yvo W Sijpkens; Jeannette G van Manen; Elisabeth W Boeschoten; Roel M Huisman; Raymond T Krediet; Friedo W Dekker
Journal:  Nephrol Dial Transplant       Date:  2007-05-21       Impact factor: 5.992

9.  Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients.

Authors:  Suzanne Heemskerk; Rosalinde Masereeuw; Olof Moesker; Martijn P W J M Bouw; Johannes G van der Hoeven; Wilbert H M Peters; Frans G M Russel; Peter Pickkers
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

10.  Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification.

Authors:  Sonoko Narisawa; Dympna Harmey; Manisha C Yadav; W Charles O'Neill; Marc F Hoylaerts; Jose Luis Millán
Journal:  J Bone Miner Res       Date:  2007-11       Impact factor: 6.741

View more
  33 in total

1.  Alkaline phosphatase and mortality in patients on peritoneal dialysis.

Authors:  Xinhui Liu; Qunying Guo; Xiaoran Feng; Juan Wang; Juan Wu; Haiping Mao; Fengxian Huang; Xueqing Yu; Xiao Yang
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

Review 2.  Does PTH offer additive value to ALP measurement in assessing CKD-MBD?

Authors:  Edmund J Lamb; Michael P Delaney
Journal:  Perit Dial Int       Date:  2014 Nov-Dec       Impact factor: 1.756

Review 3.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

4.  Prognostic significance of pre-end-stage renal disease serum alkaline phosphatase for post-end-stage renal disease mortality in late-stage chronic kidney disease patients transitioning to dialysis.

Authors:  Keiichi Sumida; Miklos Z Molnar; Praveen K Potukuchi; Fridtjof Thomas; Jun Ling Lu; Yoshitsugu Obi; Connie M Rhee; Elani Streja; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Nephrol Dial Transplant       Date:  2018-02-01       Impact factor: 5.992

Review 5.  Towards the revival of alkaline phosphatase for the management of bone disease, mortality and hip fractures.

Authors:  Wei Ling Lau; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2014-04-15       Impact factor: 5.992

6.  Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.

Authors:  Connie M Rhee; Miklos Z Molnar; Wei Ling Lau; Vanessa Ravel; Csaba P Kovesdy; Rajnish Mehrotra; Kamyar Kalantar-Zadeh
Journal:  Perit Dial Int       Date:  2014-01-02       Impact factor: 1.756

Review 7.  Fibroblast growth factor-23: what we know, what we don't know, and what we need to know.

Authors:  Csaba P Kovesdy; Leigh Darryl Quarles
Journal:  Nephrol Dial Transplant       Date:  2013-04-25       Impact factor: 5.992

8.  Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting.

Authors:  Alex R Chang; Morgan E Grams
Journal:  Am J Kidney Dis       Date:  2014-06-14       Impact factor: 8.860

9.  The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program.

Authors:  Georges Saab; Andrew S Bomback; Samy I McFarlane; Suying Li; Shu-Cheng Chen; Peter A McCullough; Adam Whaley-Connell
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

10.  Correlates of parathyroid hormone concentration in hemodialysis patients.

Authors:  Jinnan Li; Miklos Z Molnar; Joshua J Zaritsky; John J Sim; Elani Streja; Csaba P Kovesdy; Isidro Salusky; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2013-01-24       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.